Oral News and Research

RSS

Candidiasis needs to be treated early, aggressively to help vulnerable hospitalized patients

One of the most common causes of healthcare-associated infections, candidiasis is a serious, life-threatening fungal infection that needs to be treated early, aggressively and appropriately, note updated guidelines released by the Infectious Diseases Society of America and published in the journal Clinical Infectious Diseases.

17 Dec 2015

Louisville researchers move closer to potential treatment for gum disease

University of Louisville researchers recently received a patent on a synthetic biochemical compound and its variants, moving science closer to a treatment for gum disease. This discovery could lead to the formulation of a mouth rinse or tooth varnish to prevent the pathogen, P. gingivalis from colonizing in the mouth and establishing itself orally.

17 Dec 2015

Tris announces FDA approval of first-ever ER chewable tablet

Tris Pharma, Inc. is pleased to announce that the U.S. Food and Drug Administration approved the first-ever extended-release (ER) chewable tablet, capping off a highly productive year with three Tris-developed NDAs approved in a calendar year.

16 Dec 2015

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan

TaiGen Biotechnology Company, Limited today announced that together with its distribution partner, Holding Distribution, it has launched Taigexyn (nemonoxacin) capsules in Taiwan, the first market where Taigexyn is available.

16 Dec 2015

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

15 Dec 2015

New research sheds light on how gut damage can cause malnutrition, oral vaccine failure

It has been estimated that if every nutritional measure known to be helpful were applied to every child in the world, global malnutrition would be decreased by only a third. New research from the University of Virginia School of Medicine, the University of Vermont and the International Centre for Diarrhoeal Disease Research in Bangladesh sheds light on why: Damage to the gut from infection explains why food alone is not a solution to malnutrition.

15 Dec 2015

$Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma$

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Phase III trial findings suggest that patients with relapsed or refractory mantle cell lymphoma derive significantly greater benefits from ibrutinib than from temsirolimus therapy.

14 Dec 2015

Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Validus Pharmaceuticals LLC, together with Wood Creek Capital Management, LLC ("Wood Creek"), announced today the acquisition of the U.S. rights to several well-known product lines from Sanofi US: Anzemet (dolasetron mesylate) Injection and Tablets, Claforan (cefotaxime) Injection/IM/IV, Demerol (meperidine hydrochloride) Tablets, Drisdol (ergocalciferol) Capsules and Oral Solution, Hiprex (methenamine hippurate) Tablets, Lasix (furosemide) Tablets, Norpramin (desipramine hydrochloride) Tablets and Trental (pentoxifylline) Tablets.

14 Dec 2015

Access to harm reduction programs vey low in rural and suburban areas affected by HIV infections

Access to harm reduction programs such as syringe exchange is lowest in rural and suburban areas, where rates of addiction to heroin and other opioids are on the rise, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

12 Dec 2015

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).

11 Dec 2015

Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

The first Toulouse Onco Week (TOW) is due to take place from 3 to 6 February 2016 at the Pierre Baudis Congess Center, Toulouse, France. This unique event will be focused on the international fight against cancer by bringing together stakeholders from around the world and presenting the latest global innovations in oncology.

10 Dec 2015

VNS technology could help improve lives of people recovering from stroke

A new study involving UT Dallas researchers shows that vagus nerve stimulation (VNS) technology could help improve the lives of hundreds of thousands of people who suffer weakness and paralysis caused by strokes.

10 Dec 2015

More than half of women may have vulvovaginal symptoms after menopause

After menopause, more than half of women may have vulvovaginal symptoms that have a big impact on their lifestyle, emotions, and sex life. What's more, the symptoms tend to travel with other pelvic troubles, such as prolapse and urinary and bowel problems. But many women aren't getting help, shows a study published online today in Menopause, the journal of The North American Menopause Society.

9 Dec 2015

Research examines ketone esters to combat hyperbaric oxygen toxicity in Navy divers

For the first time, ketone esters-oral supplements useful in epilepsy treatment-are being studied to fight seizures caused by hyperbaric oxygen toxicity, a life-threatening byproduct of breathing too much oxygen that impacts deep-water divers.

9 Dec 2015

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Treatment with the antiplatelet agent prasugrel does not significantly reduce the rate of pain crises or severe lung complications in children with sickle cell disease, according to a report published in the New England Journal of Medicine describing one of the largest and most geographically diverse international clinical trials on sickle cell disease to date.

9 Dec 2015

New way to antagonize human nuclear receptor

On Monday 7 December the journal Nature Communications published the research findings of Eindhoven University of Technology (TU/e), Merck Research Laboratories (Merck is known as MSD outside the US and Canada) and Leiden University concerning an entirely new way of antagonizing a human nuclear receptor.

8 Dec 2015

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test.

8 Dec 2015

New technology may facilitate early detection of sickle cell disease for infants in developing countries

Researchers from Seidman Cancer Center at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine presented new research findings this weekend at the 57th Annual Meeting of the American Society of Hematology in Orlando.

8 Dec 2015

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

Oral News and Research

Candidiasis needs to be treated early, aggressively to help vulnerable hospitalized patients

Louisville researchers move closer to potential treatment for gum disease

Tris announces FDA approval of first-ever ER chewable tablet

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

New research sheds light on how gut damage can cause malnutrition, oral vaccine failure

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Access to harm reduction programs vey low in rural and suburban areas affected by HIV infections

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

VNS technology could help improve lives of people recovering from stroke

More than half of women may have vulvovaginal symptoms after menopause

Research examines ketone esters to combat hyperbaric oxygen toxicity in Navy divers

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

New way to antagonize human nuclear receptor

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

New technology may facilitate early detection of sickle cell disease for infants in developing countries

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News